Aarti Pharmalabs profit drops as derivative accounting error surfaces
Standalone net profit fell to ₹62.03 crore in Q4, while the company disclosed a ₹29.73 crore loss from a previously omitted derivative contract.
— 1 earlier story on Aarti Pharmalabs Ltd. →What's new
- Standalone Q4 profit fell to ₹62.03 crore from ₹88.85 crore a year ago.
- Full-year profit dropped to ₹176.20 crore from ₹238.03 crore in FY2025.
- The board recommended a final dividend of ₹2 per share.
Why this matters
The earnings decline reflects persistent margin pressure and higher finance costs. The belated recognition of a derivative contract, while flagged by auditors, adds a layer of governance concern to an already difficult year.
What we're watching
- Whether finance costs stabilize in the coming quarters.
- Any further disclosures regarding internal controls over derivative accounting.
- Management commentary on margin recovery paths.
The full read
Aarti Pharmalabs closed FY2026 with a sharp decline in profitability, as standalone net profit fell to ₹176.20 crore from ₹238.03 crore in FY2025. The Q4 performance was similarly weak, with profit dropping to ₹62.03 crore from ₹88.85 crore in the prior year. Management attributed the slide to margin compression and elevated finance costs. Beyond the operational results, the company disclosed a ₹29.73 crore fair value loss stemming from a derivative contract that was inadvertently omitted from the FY2025 accounts. While the auditor issued an unmodified opinion, the report includes an emphasis of matter regarding this accounting lapse. The board recommended a final dividend of ₹2 per share, maintaining its historical payout level. These results were largely anticipated by the market following earlier profit warnings, yet the combination of earnings decline and a governance-related accounting error leaves little room for optimism in the near term.
Questions answered
- What caused the derivative loss?
- Aarti Pharmalabs failed to recognize a target redemption forward contract in its FY2025 accounts. This resulted in a cumulative fair value loss of ₹29.73 crore being recognized in the current fiscal year.
- Did the auditor flag the accounting error?
- Yes, the auditor included an emphasis of matter regarding the derivative omission in their report. Despite this, they provided an unmodified opinion on the financial statements.
- How did the company's profitability change year-over-year?
- Standalone net profit for the full year fell to ₹176.20 crore from ₹238.03 crore in FY2025. Q4 standalone profit also declined to ₹62.03 crore from ₹88.85 crore in the same period last year.
- What is the dividend payout?
- The board recommended a final dividend of ₹2 per share. This represents a 40% payout, consistent with the company's prior years.
Story so far
All notes on AARTIPHARM →- 25 May 2026 · 9:09 PM IST Aarti Pharmalabs profit drops as derivative accounting error surfaces
- today Aarti Pharmalabs profit slides as costs and forex losses mount